

### AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-17 (cancelled).

18. (new) An immunological composition comprising two, three, or four distinct protein-polysaccharide conjugates, wherein each of the conjugates comprises a purified capsular polysaccharide derived from a serogroup of *N. meningitidis* conjugated to one or more a carrier protein(s), wherein at least one serogroup is W-135 or Y.

19. (new) The immunological composition of claim 18, wherein at least one of the capsular polysaccharides is from serogroup A or C.

20. (new) The immunological composition of claim 19, wherein at least one of the capsular polysaccharides is from serogroup A.

21. (new) The immunological composition of claim 19, wherein at least one of the capsular polysaccharides is from serogroup C.

22. (new) The immunological composition of claim 18, comprising two distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of serogroup W-135 and a second conjugate comprises a purified capsular polysaccharide selected from the group consisting of serogroup Y, A or C.

23. (new) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of serogroup Y.

24. (new) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of serogroup A.

25. (new) The immunological composition of claim 22, wherein the second conjugate comprises a purified capsular polysaccharide of serogroup C.
26. (new) The immunological composition of claim 18, comprising two distinct purified protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of serogroup Y and a second conjugate comprises a purified capsular polysaccharide of serogroup A or C.
27. (new) The immunological composition of claim 26, wherein the second conjugate comprises a purified capsular polysaccharide of serogroup A.
28. (new) The immunological composition of claim 26, wherein the second conjugate comprises a purified capsular polysaccharide of serogroup C.
29. (new) The immunological composition of claim 18, comprising three distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of serogroup W-135 and a second conjugate comprising a purified capsular polysaccharide selected from the group consisting of Y, A and C and a third conjugate comprising a purified capsular polysaccharide selected from the group consisting of serogroup Y, A and C, wherein the second conjugate is different from the third conjugate.
30. (new) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises Y.
31. (new) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises A.
32. (new) The immunological composition of claim 29, wherein at least one of the second conjugate and the third conjugate comprises C.

33. (new) The immunological composition of claim 18, comprising four distinct protein-polysaccharide conjugates, wherein a first conjugate comprises a purified capsular polysaccharide of serogroup W-135, a second conjugate comprises a purified capsular polysaccharide of serogroup Y, a third conjugate comprises a purified capsular polysaccharide of serogroup A, and a fourth conjugate comprises a purified capsular polysaccharide of serogroup C.